BioPharma APAC - Leading Source of Biopharmaceutical Intelligence in Asia Pacific

Biologics

South Korea’s Galux Inc. Achieves Breakthrough in AI-Driven Antibody Design for Multiple Therapeutic Targets

Pioneering AI technology successfully designs antibodies de novo for six therapeutic targets, including one without an experimentally resolved structure ...

March 18, 2025 | News

Innovent’s SYCUME® Becomes China’s First IGF-1R Antibody Approved for Thyroid Eye Disease

Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality me...

March 17, 2025 | News

Celonic Integrates Merck’s Breez™ Micro-Bioreactor to Advance mAb Development

Celonic Group, a Swiss-Based Quality contract development and manufacturing organization (CDMO), has announced that it is integrating Merck’s Breez&t...

March 13, 2025 | News

Pierre Fabre and RedRidge Bio Partner to Develop Biparatopic Antibody Drug Candidates

Pierre Fabre Laboratories and RedRidge Bio announced an exclusive R&D collaboration and license agreement to identify and develop biparatopic...

March 13, 2025 | News

Telix Pharmaceuticals Develops High-Yield Lead-212 Generator to Advance Targeted Alpha Therapy

Telix Pharmaceuticals Limited announces that it has developed and validated a breakthrough generator technology for the production of lead-212 (212Pb...

March 13, 2025 | News

GC Cell Begins Phase 1 Clinical Trial for CD5 CAR-NK Therapy GCC2005 in T-Cell Lymphomas

GC Cell , under the leadership of CEO Sungyong Won, announced today the initiation of its domestic Phase 1 clinical trial for GCC2005 (AB‑205), a no...

March 13, 2025 | News

Navigating Biologics Development: Strategies for Regulatory Success, CMC Challenges, and Tech Transfer

Click here to Register Now! As the biologics field rapidly evolves, mastering regulatory pathways, process development, and tech transfer is essential for...

March 12, 2025 | News

WuXi XDC and AbTis Partner to Advance Site-Selective ADC Conjugation

WuXi XDC Cayman Inc. ("WuXi XDC" or the "Company", stock code: 2268.HK), a leading global CRDMO (Contract Research, Development, and Manufacturing Organiza...

March 12, 2025 | News

Sichuan Kelun-Biotech’s TROP2 ADC Sacituzumab Tirumotecan Secures NMPA Approval for EGFR-Mutant NSCLC

Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (the "Company") announced that the Company's trophoblast cell-surface antigen 2 (TROP...

March 11, 2025 | News

GenAssist Gains FDA IND Clearance for First-in-Class Base Editing Therapy for Duchenne Muscular Dystrophy

GenAssist Ltd (GenAssist), a pioneering gene-editing biotechnology company specializing in genome medicines, is thrilled to announce that it has received&n...

March 07, 2025 | News

Akeso Completes Patient Enrollment for Phase III Trial of Cadonilimab as Adjuvant Therapy for Hepatocellular Carcinoma

Akeso, Inc. (9926. HK) ("Akeso" or the "Company") is pleased to announce the completion of patient enrollment for its Phase III registrational clinic...

March 06, 2025 | News

Frazier Life Sciences Launches Callio Therapeutics with $187M Series A to Advance Multi-Payload ADCs

Frazier Life Sciences launches Callio Therapeutics based on multi-payload antibody-drug conjugate technology and programs exclusively in-licensed from&nb...

March 05, 2025 | News

CStone Pharmaceuticals Doses First Patient in Global Phase I Trial of Trispecific Antibody CS2009

CStone Pharmaceuticals ("CStone", HKEX: 2616), an innovation-driven biopharmaceutical company focused on the research and development of anti-cancer therap...

March 05, 2025 | News

WuXi Biologics Introduces EffiX™ a High-Yield E. coli Expression Platform for Recombinant Proteins and Plasmid DNA Production

EffiX™ is designed to meet the industry's demand for a high-yield, stable, and non-lysogenic E. coli expression system. ...

March 04, 2025 | News

Stay Connected